Public company intelligence preview
APIMEDS PHARMACEUTICALS US INC
12 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: N/A average total compensation across covered insiders.
Governance movement
Public aggregate: 10 governance events in the last year.
Institutional ownership
Public aggregate: 7 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
APIMEDS PHARMACEUTICALS US INC is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry that now operates as a holding company with two very different businesses: a clinical-stage biopharma subsidiary, Lokahi Therapeutics, and a digital asset treasury platform, MindWave Innovations. Lokahi is developing Apitox, a bee venom-based biologic aimed first at knee osteoarthritis and potentially multiple sclerosis, while MindWave focuses on institutional Bitcoin treasury infrastructure and related digital asset services. The company is still development-stage overall, with no commercial revenue from its core operations and significant dependence on clinical progress, digital asset monetization, and outside financing.
Executive Compensation Practices
For a company like APUS, executive compensation is likely to be heavily weighted toward equity-based incentives, milestone bonuses, and retention awards, especially given the sharp increase in public company costs and stock-based compensation disclosed in the filings. In the Drug Manufacturers - Specialty & Generic space, pay is often tied to clinical and regulatory milestones, so management incentives would likely reflect achievements such as Phase III trial progress, BLA readiness, financing execution, and capital preservation rather than revenue growth. Because the company also has a digital asset segment, compensation may additionally be influenced by balance sheet growth, token or Bitcoin treasury performance, and risk-management execution, creating a more unusual mix of biotech and fintech-style metrics.
Insider Trading Considerations
Insider trading patterns in APUS may be driven by clinical trial outcomes, financing events, and digital asset volatility, all of which can create large valuation swings. Because the company has no recurring operating revenue and remains dependent on external capital, insiders may be especially sensitive to windows around IPO-related activity, PIPE tranches, related-party funding, and updates on trial timelines or regulatory filings. In the Healthcare sector, especially for early-stage drug manufacturers, trading is often constrained by material nonpublic information about trial results, FDA interactions, and partnership discussions; here, that is compounded by exposure to Bitcoin and token-related price moves, which can also affect insider behavior.
Unlock the full APUS insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.